Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

New combination treatment for recurrent ovarian cancer shows positive outcomes

New combination treatment for recurrent ovarian cancer shows positive outcomes

Age can affect response to adjuvant treatment among patients with resected melanoma

Age can affect response to adjuvant treatment among patients with resected melanoma

Common medication used to treat diabetic macular edema is less effective in Black patients

Common medication used to treat diabetic macular edema is less effective in Black patients

SARS-CoV-2 spike protein may induce analgesia

SARS-CoV-2 spike protein may induce analgesia

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

COVID-19 clinical trials show positive early results, says GlobalData

COVID-19 clinical trials show positive early results, says GlobalData

New treatment improves survival for people with common liver cancer

New treatment improves survival for people with common liver cancer

A faster and easier treatment option to prevent blindness in preterm infants

A faster and easier treatment option to prevent blindness in preterm infants

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy improves survival in patients with hepatocellular carcinoma

NCCN ORP plans to support phase II randomized trial for lung cancer patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

Intensive new combination therapy for ovarian cancer shows promising results

Intensive new combination therapy for ovarian cancer shows promising results

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Scientists use advanced imaging to track brain tumor 'turncoats'

Scientists use advanced imaging to track brain tumor 'turncoats'

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment